Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Prostate Cancer|May 13, 2020
Understanding and Improving 18F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate CancerBenjamin H Lowentritt, Michael S Kipper
Diagnostics (Basel, Switzerland)|February 26, 2025
How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT StudyBenjamin H Lowentritt, Albert Chau, Phillip Davis
Journal of Endourology|April 19, 2008
Robot-assisted radical cystectomy in women: technique and initial experienceBenjamin H Lowentritt, Erik P Castle, Michael Woods, et al.
The Journal of Urology|April 12, 2005
Variants of the exstrophy complex: a single institution experienceBenjamin H Lowentritt, P Sean Van Zijl, Dominic Frimberger, et al.
Journal of Health Economics and Outcomes Research|September 13, 2024
Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology SettingBenjamin H Lowentritt, Carmine Rossi, Erik Muser, et al.
Journal of Comparative Effectiveness Research|January 16, 2026
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamideBenjamin H Lowentritt, Sabree Burbage, Ibrahim Khilfeh, et al.
BJUI Compass|March 19, 2025
Genomic prostate score and treatment selection in favourable intermediate-risk prostate cancerEric Margolis, Benjamin H Lowentritt, Christopher M Pieczonka, et al.
Future Oncology (London, England)|June 11, 2024
Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamideBenjamin H Lowentritt, Shawn Du, Carmine Rossi, et al.
Therapeutic Advances in Medical Oncology|May 25, 2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancerMehmet A Bilen, Benjamin H Lowentritt, Sabree Burbage, et al.
Future Oncology (London, England)|March 15, 2024
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocolDaniel E Spratt, Tanya Dorff, Rana R McKay, et al.
Pageof 2